Connect With Us

Inside INdiana Business
Subscribe Now Log In
  • Home
  • News
    • Education
    • Health
    • Tech
    • STEM
    • Advanced Manufacturing & Logistics
    • Life Sciences
    • Ag INnovation
    • INPower
  • Videos
  • Big Wigs
    • Submit Big Wigs
  • Events
    • Engage Southwest Indiana – Evansville
    • Engage Northwest Indiana – Valparaiso
    • Engage Greater Lafayette – West Lafayette
    • Engage West Central Indiana – Terre Haute
    • Engage South Bend – Elkhart
    • Engage Northeast Indiana – Fort Wayne
    • Engage Central Indiana – Indianapolis
  • Newsletters
  • Podcasts
  • On-Air
    • TV & Radio Listings
  • Contact
    • About IIB
    • Meet the Team
    • Contact Us
    • Advertise
    • Gift Cards
    • Flagship Stations
    • Gerry’s Message
    • Speaking Engagement Request

Connect With Us

Lilly COVID Antibody Trial Ends

Tuesday, October 27, 2020 09:11 AM EDT
By Alex Brown
Lilly COVID Antibody Trial Ends (WISH-TV Photo)

A clinical trial involving an antibody treatment developed by Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has ended. The trial, sponsored by the National Institute of Allergy and Infectious Diseases, was closed following a recommendation from the independent Drug and Safety Monitoring Board, which said the treatment had a “low likelihood that the intervention would be of clinical value in this hospitalized patient population.”

The ACTIV-3 clinical trial had been paused earlier this month, though a specific reason for the pause was not given. 

The study was evaluating the efficacy of the treatment, known as LY-CoV555, in hospitalized COVID-19 patients. The NIAID, which is part of the National Institutes of Health, says the treatment showed a “lack of clinical benefit” in a hospitalized population. 

Enrollment in the study ended with 326 total participants, who will continue to be followed until 90 days have passed since the study began.

Meanwhile, the antibody treatment, also known as bamlanivimab, continues to be studied in several other trials, which will are continuing on. Among them is an ACTIV-2 study also sponsored by the NIH, to which the NIAID said the safety board did not recommend any changes.

Lilly says the treatment is also being studied in BLAZE-1, a Phase 2 trial for people recently diagnosed with COVID-19 in the non-hospitalized setting, as well as BLAZE-2, a Phase 3 trial for the prevention of COVID-19 in residents and staff at long-term care facilities.

“While there was insufficient evidence that bamlanivimab improved clinical outcomes when added to other treatments in hospitalized patients with COVID-19, we remain confident based on data from Lilly’s BLAZE-1 study that bamlanivimab monotherapy may prevent progression of disease for those earlier in the course of COVID-19,” Lilly said in a statement late Monday.

The antibody treatment was discovered by Vancouver-based AbCellera Biologics and is being developed and manufactured by Lilly in partnership with AbCellera.

Story Continues Below

Most Popular Stories

  • Next vehicle – lease or buy?

  • Hicks: Effects of strike could be felt beyond UAW workers

  • On My Way Pre-K reaches record enrollment following expanded eligibility

  • Carmel teen support foundation adds small group programs

  • North Manchester restaurant has new ownership, expansion plans

  • Federal grant to boost development at Cass County Agribusiness Park

Perspectives

Biodefense Commission heads to IMS for a public meeting on the perpetual race against biological threats

Biodefense Commission heads to IMS for a public meeting on the perpetual race against biological threats

The Indianapolis Motor Speedway has hosted countless legendary events for well over 100 years. Along with Lucas Oil Stadium, Gainbridge Fieldhouse and the Indiana Convention Center, Indianapolis hosts countless large scale, mass-gathering events. It is part of what makes this city so dynamic and special. ...

Inside INdiana Business

Inside INdiana Business
A division of IBJ Media

1 Monument Circle, Suite 300
Indianapolis, IN 46204

PHONE: (317) 634-6200

FAX: (317) 263-5060

NEWSLETTER@IIBNEWS.COM

  • Home
  • News
  • Videos
  • Gerry Dick
  • Newsletters
  • On-Air
  • Contact

Copyright © 2023 All Rights Reserved Privacy Policy | Terms of Service